AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The company traded as high as $13.50 and last traded at $13.09, with a volume of 688075 shares traded. The stock had previously closed at $12.46.
Wall Street Analyst Weigh In
Separately, HC Wainwright lifted their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, January 10th.
Read Our Latest Research Report on AngioDynamics
AngioDynamics Stock Performance
The company has a market cap of $446.79 million, a PE ratio of -1.96 and a beta of 0.60. The firm has a fifty day simple moving average of $9.81 and a 200 day simple moving average of $8.11.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to analysts' expectations of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm's revenue was down .1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) EPS. As a group, equities analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.
Insider Buying and Selling at AngioDynamics
In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On AngioDynamics
Several hedge funds and other institutional investors have recently modified their holdings of ANGO. Segall Bryant & Hamill LLC lifted its stake in shares of AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock valued at $7,091,000 after purchasing an additional 535,958 shares in the last quarter. Millennium Management LLC lifted its stake in shares of AngioDynamics by 41.9% in the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock valued at $10,850,000 after purchasing an additional 529,861 shares in the last quarter. Systematic Financial Management LP lifted its stake in shares of AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier's stock valued at $18,752,000 after purchasing an additional 300,785 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of AngioDynamics by 28.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in shares of AngioDynamics by 10.8% in the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after purchasing an additional 96,138 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.
About AngioDynamics
(
Get Free Report)
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Featured Stories
Before you consider AngioDynamics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.
While AngioDynamics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
